A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
NCT07424404
This study is recruiting at 13 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of Xanomeline and Trospium Chloride for the treatment of psychiatric disorders in children and adolescents
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
- Autism-Related Irritability
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 5 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Last updated on ClinicalTrials.gov
- October 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 4
- Advanced Research Center Inc. · Anaheim, CA
- Inland Psychiatric Medical Group. · Chino, CA
- Proscience Research Group · Culver City, CA
- UCSF Neurosciences Clinical Research Unit (NCRU) · San Francisco, CA
Florida · 1
- Apg Research, Llc · Orlando, FL
Georgia · 3
- Atlanta Center for Medical Research · Atlanta, GA
- Salveo Integrative Health - Lawrenceville · Lawrenceville, GA
- Denali Health Atlanta, LLC · Stone Mountain, GA
Illinois · 1
- EmVenio Research Center - Prime Healthcare · Chicago, IL
Massachusetts · 1
- Boston Children's Hospital · Boston, MA
Ohio · 1
- University of Cincinnati Cancer Institute · Cincinnati, OH
Texas · 2
- VAST Clinical Research · Garland, TX
- Evolution Research Group · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.